~~<i id='EA91F4AA0A'><strike id='EA91F4AA0A'><tt id='EA91F4AA0A'><pre id='EA91F4AA0A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：knowledge 2025-09-29 01:07:44 - browse：8934

Allergan, Dom Smith/STAT

It wasn’t supposed to work out this way for Brent Saunders.

Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： AstraZeneca chief proposes a novel edit to the drug pricing bill

hotspot

focus

leisure time

knowledge

Clockwisefromtopleft:STAT'sNicholasSt.Fleur(moderator);JudySewards,headofclinicaltrialexperienceatPf

WSS

Crinetics acromegaly drug succeeds in late

Biden report: The neurospychology of memory and aging

Senators start work on Medicare physician payment reform

NIH nominee Bertagnolli will get October confirmation hearing

Covid hospitalizations on the rise, Humana says

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

focus

hotspot

hotspot

Activists slam private health insurers over coverage restrictions

Amazon on where the company's health care bets are headed next

Medical leaders decry Supreme Court decision on affirmative action

Advances in CAR

In age of alternative facts, a scholarly course on calling out crap

Robert F. Kennedy is pitching centrism on health, even on abortion

What does generative AI mean for health care? We asked experts

Biden report: The neurospychology of memory and aging

Affirmative action in medical school literally saved lives

BioAge raises $170M for combination therapy with Zepbound

hotspot

House transparency, PBM reform bill gains bipartisan support

A disappointing year of Humira biosimilars

What should King Charles tell the public about his cancer?

Medicare Advantage proposed rates disappoint insurers

For Medicare Advantage, Democrats want stronger protections around AI

What drug price negotiations mean for Medicare Part D

focus

focus

leisure time

knowledge